Advancing Oral Lipid-Based Therapies in Psoriasis: Overcoming Placebo Barriers & Unlocking Durable Efficacy
- Advancing a first-in-class oral phospholipid therapy (HRO350) targeting inflammatory resolution pathways in mild-to-moderate psoriasis, offering a non-immunosuppressive alternative with a favourable long-term safety profile
- Demonstrating durable clinical and biological effects through extended follow-up data, highlighting sustained skin improvement and disease control beyond short-term symptom suppression
- Addressing high placebo response as a trial-design consideration by refining endpoint selection, population enrichment, and longitudinal outcome measures to strengthen signal detection in oral psoriasis programs